These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 16940806

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M.
    BMC Cancer; 2006 Sep 15; 6():225. PubMed ID: 16978400
    [Abstract] [Full Text] [Related]

  • 4. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
    Gebbia V, Boussen H, Valerio MR.
    Anticancer Res; 2012 Feb 15; 32(2):529-36. PubMed ID: 22287742
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B.
    Cancer J; 2008 Feb 15; 14(1):62-8. PubMed ID: 18303485
    [Abstract] [Full Text] [Related]

  • 8. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ.
    Clin Cancer Res; 2006 May 15; 12(10):3092-8. PubMed ID: 16707607
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Maintenance treatment in metastatic breast cancer.
    Sánchez-Muñoz A, Pérez-Ruiz E, Ribelles N, Márquez A, Alba E.
    Expert Rev Anticancer Ther; 2008 Dec 15; 8(12):1907-12. PubMed ID: 19046111
    [Abstract] [Full Text] [Related]

  • 13. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.
    J Clin Oncol; 2009 Dec 10; 27(35):5906-10. PubMed ID: 19858391
    [Abstract] [Full Text] [Related]

  • 14. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
    Fousseyni T, Diawara M, Pasquier E, André N.
    J Pediatr Hematol Oncol; 2011 Jan 10; 33(1):31-4. PubMed ID: 21164360
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A, Mancini P, Ferrari P, Anselmi L, Tartarelli G, Bonazzi V, Carpi A, Giardino R.
    Biomed Pharmacother; 2004 Oct 10; 58(8):447-50. PubMed ID: 15464874
    [Abstract] [Full Text] [Related]

  • 18. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ, Hu P, Osborne CK, Falkson G, Tormey DC, Eastern Cooperative Oncology Group.
    Am J Clin Oncol; 2007 Apr 10; 30(2):113-25. PubMed ID: 17414459
    [Abstract] [Full Text] [Related]

  • 19. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
    Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S.
    Breast J; 2006 Apr 10; 12(6):531-5. PubMed ID: 17238982
    [Abstract] [Full Text] [Related]

  • 20. [Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].
    Brockmann B, Geschke E, Schmidt UM, Ebeling K.
    Geburtshilfe Frauenheilkd; 1991 May 10; 51(5):383-6. PubMed ID: 1869008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.